002932 明德生物
2024/06 - 中期2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)1.0931.19690.61472.64854.800
总资产报酬率 ROA (%)0.9100.90466.73958.35345.415
投入资产回报率 ROIC (%)1.0681.13484.56867.58535.171

边际利润分析
销售毛利率 (%)55.41854.27866.84675.01578.209
营业利润率 (%)45.44519.37148.24059.99758.626
息税前利润/营业总收入 (%)40.68219.35647.87659.67457.772
净利润/营业总收入 (%)35.5049.23541.60051.12349.591

收益指标分析
经营活动净收益/利润总额(%)-85.50321.010118.847100.88399.416
价值变动净收益/利润总额(%)81.96389.4560.7460.0400.235
营业外收支净额/利润总额(%)-3.533-3.792-0.068-0.192-1.002

偿债能力分析
流动比率 (X)3.2622.6983.2485.4953.937
速动比率 (X)3.0932.5713.1394.9743.556
资产负债率 (%)11.60714.81726.34916.59421.853
带息债务/全部投入资本 (%)1.0131.1316.9063.398--
股东权益/带息债务 (%)9,654.0378,631.6771,336.1842,821.838651.091
股东权益/负债合计 (%)732.955550.562268.294491.842353.403
利息保障倍数 (X)-12.66827.931-144.295-287.170-212.237

营运能力分析
应收账款周转天数 (天)1,283.173905.10256.38058.4840.000
存货周转天数 (天)330.120203.37427.998102.4270.000